Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

How BioCryst Pharmaceuticals Blew Away Expectations in Q4

TheMotleyFool

0 0

How BioCryst Pharmaceuticals Blew Away Expectations in Q4Photo, wide shot, wide-angle lens, Clinical research organization, sunset photo at golden hour, photo by Peter Lik: https://img.midjourneyapi.xyz/temp/02f7778c-d723-4fb3-bdef-fabb7e5fc9c8.png

BioCryst Pharmaceuticals (NASDAQ: BCRX) is off to a good start in 2020 after an abysmal performance in 2019. The biotech stock enjoyed a nice boost after BioCryst filed for regulatory approval in Japan for berotralstat as a prophylactic treatment of hereditary angioedema (HAE). Investors' interest has also picked up with the potential for the company's early-stage drug galidesivir in treating the new coronavirus, COVID-19.

Now there's even more good news for BioCryst. The company announced its 2019 fourth-quarter and full-year results before the market opened on Thursday. Here are the highlights from BioCryst's Q4 update.

Image source: Getty Images.

Source Fool.com

Like: 0

BCRX

Teilen